0YC0.L

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Pharmaceuticals

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$6M	+1138.1%	$-0.68	$-0.68–$-0.68	—	1
2027	$20M	+220.8%	$-0.12	$-0.12–$-0.12	—	1
2028	$9M	-54.7%	$0.15	$0.15–$0.15	—	1
2029	$15M	+66.7%	$0.30	$0.30–$0.30	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-04-22	$-0.40	$-0.43	-8.2%
2025-03-07	$-0.39	$-0.50	-29.7%
2024-11-05	$-0.40	$-0.38	+4.7%
2024-08-07	$-0.46	$-0.31	+32.0%
2024-05-15	$-0.61	$-0.34	+43.1%
2024-03-13	$-0.69	$-0.59	+14.3%
2023-11-14	$-0.86	$-1.05	-22.0%
2023-08-09	$-0.80

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
0YC0.LUnity Biotechnology, Inc.	$0.06	+0.00%	$1M	—
0A4X.LDMK Pharmaceuticals Corporation	$0.00	+0.00%	$10	—
0H8E.LAccelerate Diagnostics, Inc.	$0.01	+0.80%	$25	—
0HUZ.LImunon, Inc.	$0.88	-5.44%	$2M	—
0JDB.LInvitae Corporation	$0.00

Unity Biotechnology, Inc.

Unity Biotechnology, Inc. is a biotechnology firm dedicated to discovering and advancing therapies designed to slow, halt, or even reverse the progression of diseases associated with aging. The company's primary therapeutic candidate, UBX1325, is currently undergoing Phase II clinical trials, addressing age-related ocular conditions such as diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Its pipeline also features UBX1967, intended for various ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody targeting age-related vision impairments; and UBX2089, an a-Klotho hormone candidate with potential in diverse neurological applications. Originally incorporated in 2009 as Forge, Inc., the company adopted its current name, Unity Biotechnology, Inc., in January 2015 and operates from its headquarters in South San Francisco, California.

unitybiotechnology.com

Employees: 16
IPO / List date: Oct 4, 2018
HQ: US

Held by traders on TradeandTell

No one on the platform currently holds 0YC0.L.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 0YC0.L as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 0YC0.L yet.